Latest Breaking News On - Tevard biosciences - Page 6 : comparemela.com

UCB and Zogenix: UCB to acquire Zogenix

- Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines and

Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES

Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome.

Epilepsy: Sudden Unexpected Death Linked to Heart Variability Measures

Quantification may help stratify SUDEP risk People who died due to sudden unexpected death in epilepsy (SUDEP) had changes in frequency-domain measures of heart rate variability compared with living epilepsy controls, a retrospective, nested case-control study found. Compared with non-SUDEP epilepsy controls, epilepsy patients who died with SUDEP had lower normalized awake low-frequency power (LFP)

Chutes & Ladders—Another Novartis exec answers the biotech call, this time for gene therapy startup Tevard

Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday.

Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine) Oral Solution